Receptor.AI announces a new collaboration with Lubrizol Corporation, focused on peptide-based skin care solutions.
Together, they will explore the future of AI-guided peptide innovation, combining Lubrizol’s deep expertise in skin science with Receptor.AI’s discovery platform to accelerate the identification and refinement of novel bioactive peptides.
Receptor.AI brings robust expertise and technologies to evaluate peptide performance and delivery, ensuring candidates are optimized not only for activity and stability but also for effective integration into formulations.
Receptor.AI’s peptide platform, PEPTOR™, provides an end-to-end workflow from initial design to late-stage activity and PK optimization. Powered by AI-guided peptide mutation across a library of more than 10,000 NNCAs and non-amino acid substitutes, PEPTOR™ also supports a wide range of chemical modifications – including flexible linkages and diverse forms of peptide cyclization – enabling exploration of rich chemical space and innovative peptide designs.
Lubrizol Corporation, a Berkshire Hathaway company, brings deep expertise in skin health and materials science, making this collaboration a significant step toward advancing innovative peptide solutions for skin health and beyond.
Receptor.AI is a Massachusetts-based next-generation TechBio company transforming drug discovery through AI-native infrastructure and deep modality expertise. With a validated track record across more than 40 discovery programs, the company integrates machine learning, physics-based modeling, and automated decision-making into a unified R&D platform. Receptor.AI drives innovation across small molecules, peptides, and induced-proximity therapeutics, partnering with global biopharma and academic institutions to unlock challenging targets and accelerate the path from concept to clinic. More information is available at https://www.receptor.ai .